Among patients with HCV genotypes 2 or 3, does sofosbuvir plus ribavirin result in sustained virologic response?
Among patients with HCV genotypes 2 or 3, sofosbuvir plus ribavirin resulted in high rates of sustained virologic response.
Historically, approximately three-quarters of patients with HCV genotypes 2 or 3 treated with peginterferon alfa-2a (IFN) plus ribavirin achieved a sustained virologic response (SVR). However, IFN-related toxicities, including influenza-like symptoms, depression, anemia, thrombocytopenia, and autoimmune thyroiditis, were prohibitive. In the 2010s, novel antiviral therapies were being developed, including the viral RNA synthesis inhibitor sofosbuvir, with marked efficacy and reasonable tolerability. Sofosbuvir's single-agent activity and its efficacy in combination with ribavirin led to a flurry of publications touting an IFN-free cure for HCV. Its use in North America and other centers in the FISSION studies established sofosbuvir-ribavirin as a reasonable IFN-sparing regimen among patients with HCV genotypes 2 or 3.
VALENCE was designed as phase 3 study randomizing patients with HCV genotypes 2 or 3 to sofosbuvir plus either ribavirin or placebo for a total of 12 weeks. However, results of the FUSION study suggested that genotype 3 patients should receive 24 rather than 12 weeks of therapy, and therefore the protocol was amended such that genotype 3 patients received sobosbuvir-ribavirin for 24 weeks; consequently, the genotype 3 arm was changed to a descriptive study. Although the genotype 2 arm could have theoretically remained a randomized study, the investigators modified this as well by removing the placebo group and providing 12 weeks of sofosbuvir-ribavirin to consenting patients with genotype 2 infections. After 12 weeks of therapy, SVR was achieved in 93% of genotype 2 patients and in 27% of genotype 3 patients. Among genotype 3 patients treated for 24 weeks, SVR was 85%. In general, the therapy was well tolerated; adverse events led to treatment discontinuation in about 1% of each arm.
The high cost of sofosbuvir has been a matter of controversy as it retails for $1,000 per pill in the US. However, this has not precluded its incorporation into US guidelines.
AASLD/IDSA HCV (2014-10, adapted)
- Initial HCV treatment:
- Genotype 2:
- Recommended: Sofosbuvir-ribavirin x 12 weeks (class I, level A)
- Alternative: None
- Genotype 3:
- Recommended: Sofosbuvir-ribavirin x 24 weeks (Ilass B, level )
- Alternative: Sofosbuvir-ribavirin plus IFN x 12 weeks (class IIa, level A)
- Genotype 2:
- Retreatment of HCV in IFN/ribavirin non-responders:
- Genotype 2:
- Recommended: Sofosbuvir-ribavirin for 12 weeks; consider extension to 16 weeks in patients with cirrhosis (class I, level A)
- Alternative: Sofosbuvir-ribavirin plus IFN x 12 weeks (class IIa, level B)
- Genotype 3:
- Recommended: Sofosbuvir-ribavirin for 24 weeks (class IIa, level A)
- Alternative: Sofosbuvir-ribavirin plus IFN w eekly for 12 weeks (class IIa, level B)
- Genotype 2:
- Multicenter, blinded, randomized (initially), controlled phase 3 trial, later amended to an unblinded descriptive study with the placebo group terminated
- N=419 patients with genotype 2 or 3
- Genotype 2 on sofosbuvir + ribavirin for 12 weeks (n=73)
- Genotype 3 on sofosbuvir + ribavirin for 12 weeks (n=11)
- Genotype 3 on sofosbuvir + ribavirin for 24 weeks (n=250)
- Genotype 2 or 3 on placebo (n=85)
- Setting: 77 centers in Europe
- Enrollment: 2012-2013
- Follow-up: Weeks 2 and 4 during treatment; weeks 4 and 12 after treatment
- Analysis: Not explicitly stated, presumably intention-to-treat
- Primary outcome: HCV RNA <25 IU/mL 4 and 12 weeks after completing 12 weeks of treatment
- Age ≥18 years
- Chronic HCV genotype 2 or 3, regardless of prior treatments for HCV
- HCV RNA ≥10,000 IU/mL
- BMI ≥18 kg/m2
- HbA1c ≤10%
- EKG without clinically-significant findings
- ALT and AST ≤10×ULN
- Hgb ≥12 g/dL for male, Hgb ≥11 g/dL for female
- Plts >50×103/mm3
- INR ≤1.5×ULN (unless known hemophilia or stable anticoagulant regimen)
- Albumin ≥3 g/dL
- Direct bilirubin ≤1.5×ULN
- CrCl ≥60 mL/min
- Prior treatment with an antiviral medication targeting NS5B polymerase
- Pregnant or nursing female or male with a pregnant female partner
- Non-HCV-related chronic liver disease
- HBV or HIV infection
- RBV contraindication
- Cancer diagnosed or treated in prior 5 years (except cervical carcinoma in situ or non-melanoma skin cancer)
- Clincially-significant hemoglobinopathy
- Chronic immunosuppression
- Drug or alcohol abuse within 12 moths
- Solid organ transplant
- History of hepatic decompensation (eg, uGIB)
- Clinically-significant illness or other disorder that would prevent with trial participation
- GI disorder that would prevent drug absorption
- Significant pulmonary or cardiac disease
- >3 drinks of alcohol/day if female or >4/day if male
- Difficulty with blood collection
- Loss or donation of >400 mL/blood in the prior 2 months
- Use of prohibited medications that cause medication concentration modifications
From the placebo group. Groups were similar.
- Demographics: Age 49 years, White race 95%, Hispanic or Latino 12%
- Health data: BMI 26 kg/m2
- HCV data: Genotype 2 (21%), genotype 3 (79%), RNA 6.5 log10IU/mL, cirrhosis 20%, ALT >1.5x ULN 62%
- Prior IFN treatment: None 41%, yes 59% (discontinuation for side effects 0%, no response 21%, relapse or breakthrough 38%)
- The original design randomized patients in a 4:1 ratio to a group with stratification by cirrhosis and prior HCV treatment:
- Given the results of the FUSION trial, the trial was redesigned as a descriptive study with no hypothesis testing and the placebo arm was terminated
Comparisons are genotype 2 vs. genotype 3. Data is from the active treatment groups only as placebo viral loads were not measured.
- HCV RNA <25 IU/mL 4 weeks after 12 weeks of treatment
- 93% vs. 45%
- HCV RNA <25 IU/mL 12 weeks after 12 weeks of treatment
- 93% vs. 27%
- HCV RNA <25 IU/mL 4 weeks after 24 weeks of treatment
- Genotype 3: 87% (95% CI 82-91%)
- HCV RNA <25 IU/mL 12 weeks after 24 weeks of treatment
- Genotype 3: 85% (95% CI 80-89%)
- HCV RNA <25 IU/mL 2 weeks into 12 weeks of treatment
- 78% vs. 55%
- HCV RNA <25 IU/mL 2 weeks into 24 weeks of treatment
- Genotype 3: 86% (95% CI 81-90%)
- HCV RNA <25 IU/mL 4 weeks into 12 weeks of treatment
- 100% in both genotypes
- HCV RNA <25 IU/mL 4 weeks into 24 weeks of treatment
- Genotype 3: 99% (95% CI 96-99%)
Presented as placebo vs. sofosbuvir + ribavirin for 12 weeks vs. sofosbuvir + ribavirin for 24 weeks.
- 71% vs. 86% vs. 92%
- Resulting in discontinuation: 1% vs. 1% vs. <1%
- Serious: 2% vs. 0% vs. 4%
- Most common
- Headache: 27% vs. 29% vs. 30%
- Fatigue: 19% vs. 23% vs. 30%
- Pruritis: 9% vs. 24% vs. 27%
- Asthenia: 5% vs. 25% vs. 21%
- Nausea: 11% vs. 31% vs. 13%
- Insomnia: 2% vs. 11% vs. 16%
- Original design was revised providing no hypothesis testing nor formal statistical comparisons
- Few liver biopsies in this population
- Among patients with genotype 2 infection, it is unclear if longer duration or addition of IFN would benefit patients
Gilead Sciences, the manufacturers of Sovaldi (the brand name of sofosbuvir)
- Fried MW, et al. "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection." The New England Journal of Medicine. 2002;347(13):975-982.
- Wilkins T, et al. "Hepatitis C: Diagnosis and treatment." American Family Physician. 2010;81(11):1351-1357.
- Lawitz E, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16;368(20):1878-87.
- Hoofnagle JH and Sherker AH. "Therapy for hepatitis C -- The costs of success." The New England Journal of Medicine. 2014;370(16):1552-1553.
- AASLD/IDSA writers. "Recommendations for testing, managing, and treating hepatitis C." hcvguidelines.org. Revised 2014-10-24. Accessed 2014-12-01.
- Jacobson IM, et al. "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options." The New England Journal of Medicine. 2013;368(20):1867-1877.
- ClinicalTrials.gov listing NCT01682720. Accessed 2014-12-01.